Physician profile
John D Dimenna
NPI 1649222332
$616.43
in general payments reported to CMS, 2019-2025
14 companies · $29.15 in 2025
The $29.15 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2023: $57.81 · 2024: $15.87 · 2025: $29.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.64 | 2019 | |
| Amgen INC. | $69.13 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.57 | 2019 | |
| Abbott Laboratories | $44.98 | 2023-2025 | Mitraclip, Jot Dx |
| Astrazeneca Pharmaceuticals LP | $43.07 | 2019-2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $42.50 | 2023-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $33.23 | 2019 | |
| Astellas Pharma US INC | $31.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.25 | 2019 | |
| Amarin Pharma, INC. | $17.91 | 2019 | |
| Irhythm Technologies, INC. | $17.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dimenna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.